ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).
Sector:
Health Technology
Industry:
Pharmaceuticals Other
Employees:
Frequently Asked Questions
What is Market Cap of Arqule Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Arqule Inc. market cap is N/A.
What is the 52-week high for Arqule Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Arqule Inc. 52 week high is N/A as of September 28, 2025.
What is the 52-week low for Arqule Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Arqule Inc. 52 week low is N/A as of September 28, 2025.
What was Arqule Inc. stock price yesterday?
Arqule Inc. stock price yesterday was $20.00.
What is the PE ratio of Arqule Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Arqule Inc.’s P/E ratio is None.
What is the Price-to-Book ratio of Arqule Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Arqule Inc. P/B ratio is None.
What is Arqule Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Arqule Inc.'s EBITDA is -19.14.
What is the 50-day moving average of Arqule Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Arqule Inc. 50-day moving average is N/A.
